{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T16:20:16Z","timestamp":1792686016312,"version":"4.5.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T00:00:00Z","timestamp":1366156800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2013,12]]},"DOI":"10.1186\/1471-2407-13-195","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T13:56:51Z","timestamp":1366207011000},"source":"Crossref","is-referenced-by-count":46,"title":["A novel IgE antibody targeting the prostate-specific antigen as a potential prostate cancer therapy"],"prefix":"10.1186","volume":"13","author":[{"given":"Tracy R","family":"Daniels-Wells","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Helguera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K","family":"Leuchter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafaela","family":"Quintero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maggie","family":"Kozman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 A","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Ortiz-S\u00e1nchez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Otoniel","family":"Mart\u00ednez-Maza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Birgit C","family":"Schultes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher F","family":"Nicodemus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuel L","family":"Penichet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,4,17]]},"reference":[{"issue":"1","key":"3857_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.20138","volume":"62","author":"R Siegel","year":"2012","unstructured":"Siegel R, Naishadham D, Jemal A: Cancer statistics, 2012. CA Canc J Clin. 2012, 62 (1): 10-29. 10.3322\/caac.20138.","journal-title":"CA Canc J Clin"},{"key":"3857_CR2","first-page":"187","volume":"5","author":"J Singh","year":"2010","unstructured":"Singh J, Trabulsi EJ, Gomella LG: Is there an optimal management for localized prostate cancer?. Clin Interv Aging. 2010, 5: 187-197.","journal-title":"Clin Interv Aging"},{"issue":"12","key":"3857_CR3","doi-asserted-by":"publisher","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-10-2815","volume":"17","author":"C Massard","year":"2011","unstructured":"Massard C, Fizazi K: Targeting continued androgen receptor signaling in prostate cancer. Clin Cancer Res. 2011, 17 (12): 3876-3883. 10.1158\/1078-0432.CCR-10-2815.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"3857_CR4","first-page":"131","volume":"63","author":"M Bishr","year":"2011","unstructured":"Bishr M, Lattouf JB, Gannon PO, Saad F: Updates on therapeutic targets and agents in castration-resistant prostate cancer. Minerva Urol Nefrologica Ital J Orol Nephrol. 2011, 63 (2): 131-143.","journal-title":"Minerva Urol Nefrologica Ital J Orol Nephrol"},{"issue":"8","key":"3857_CR5","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1517\/14712598.2011.575357","volume":"11","author":"G Sonpavde","year":"2011","unstructured":"Sonpavde G, Agarwal N, Choueiri TK, Kantoff PW: Recent advances in immunotherapy for the treatment of prostate cancer. Expert Opin Biol Ther. 2011, 11 (8): 997-1009. 10.1517\/14712598.2011.575357.","journal-title":"Expert Opin Biol Ther"},{"key":"3857_CR6","first-page":"79","volume":"4","author":"S Gupta","year":"2011","unstructured":"Gupta S, Carballido E, Fishman M: Sipuleucel-T for therapy of asymptomatic or minimally symptomatic, castrate-refractory prostate cancer: an update and perspective among other treatments. Oncol Targets Ther. 2011, 4: 79-96.","journal-title":"Oncol Targets Ther"},{"issue":"11","key":"3857_CR7","doi-asserted-by":"publisher","first-page":"3520","DOI":"10.1158\/1078-0432.CCR-10-3126","volume":"17","author":"MA Cheever","year":"2011","unstructured":"Cheever MA, Higano CS: PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res. 2011, 17 (11): 3520-3526. 10.1158\/1078-0432.CCR-10-3126.","journal-title":"Clin Cancer Res"},{"issue":"38","key":"3857_CR8","doi-asserted-by":"publisher","first-page":"6485","DOI":"10.1016\/j.vaccine.2011.06.088","volume":"29","author":"M Bilusic","year":"2011","unstructured":"Bilusic M, Heery C, Madan RA: Immunotherapy in prostate cancer: emerging strategies against a formidable foe. Vaccine. 2011, 29 (38): 6485-6497. 10.1016\/j.vaccine.2011.06.088.","journal-title":"Vaccine"},{"issue":"4","key":"3857_CR9","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/nrc2351","volume":"8","author":"H Lilja","year":"2008","unstructured":"Lilja H, Ulmert D, Vickers AJ: Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev. 2008, 8 (4): 268-278. 10.1038\/nrc2351.","journal-title":"Nat Rev"},{"issue":"10","key":"3857_CR10","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1093\/clinchem\/41.10.1480","volume":"41","author":"K Pettersson","year":"1995","unstructured":"Pettersson K, Piironen T, Seppala M, Liukkonen L, Christensson A, Matikainen MT, Suonpaa M, Lovgren T, Lilja H: Free and complexed prostate-specific antigen (PSA): in vitro stability, epitope map, and development of immunofluorometric assays for specific and sensitive detection of free PSA and PSA-alpha 1-antichymotrypsin complex. Clin Chem. 1995, 41 (10): 1480-1488.","journal-title":"Clin Chem"},{"issue":"8","key":"3857_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S1043-2760(98)00082-4","volume":"9","author":"EP Diamandis","year":"1998","unstructured":"Diamandis EP: Prostate-specific antigen: its usefulness in clinical medicine. Trends Endocrinol Metab TEM. 1998, 9 (8): 310-316. 10.1016\/S1043-2760(98)00082-4.","journal-title":"Trends Endocrinol Metab TEM"},{"issue":"9","key":"3857_CR12","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1093\/clinchem\/41.9.1273","volume":"41","author":"Z Chen","year":"1995","unstructured":"Chen Z, Prestigiacomo A, Stamey TA: Purification and characterization of prostate-specific antigen (PSA) complexed to alpha 1-antichymotrypsin: potential reference material for international standardization of PSA immunoassays. Clin Chem. 1995, 41 (9): 1273-1282.","journal-title":"Clin Chem"},{"issue":"3A","key":"3857_CR13","first-page":"1551","volume":"20","author":"A Katzenwadel","year":"2000","unstructured":"Katzenwadel A, Schleer H, Gierschner D, Wetterauer U, Elsasser-Beile U: Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer. Anticancer Res. 2000, 20 (3A): 1551-1555.","journal-title":"Anticancer Res"},{"issue":"2A","key":"3857_CR14","first-page":"893","volume":"19","author":"AA Sinha","year":"1999","unstructured":"Sinha AA, Quast BJ, Reddy PK, Elson MK, Wilson MJ: Intravenous injection of an immunoconjugate (anti-PSA-IgG conjugated to 5-fluoro-2'-deoxyuridine) selectively inhibits cell proliferation and induces cell death in human prostate cancer cell tumors grown in nude mice. Anticancer Res. 1999, 19 (2A): 893-902.","journal-title":"Anticancer Res"},{"issue":"3","key":"3857_CR15","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1006\/clim.2001.5115","volume":"101","author":"KA Berlyn","year":"2001","unstructured":"Berlyn KA, Schultes B, Leveugle B, Noujaim AA, Alexander RB, Mann DL: Generation of CD4(+) and CD8(+) T lymphocyte responses by dendritic cells armed with PSA\/anti-PSA (antigen\/antibody) complexes. Clin Immunol (Orlando, Fla). 2001, 101 (3): 276-283. 10.1006\/clim.2001.5115.","journal-title":"Clin Immunol (Orlando, Fla)"},{"issue":"5","key":"3857_CR16","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1038\/nri2744","volume":"10","author":"LM Weiner","year":"2010","unstructured":"Weiner LM, Surana R, Wang S: Monoclonal antibodies: versatile platforms for cancer immunotherapy. Nat Rev Immunol. 2010, 10 (5): 317-327. 10.1038\/nri2744.","journal-title":"Nat Rev Immunol"},{"key":"3857_CR17","doi-asserted-by":"crossref","unstructured":"Helguera G, Daniels TR, Rodriguez JA, Penichet ML: Edited by: Flickinger M. 2010, New York: John Wiley & Sons, Inc, 3526-42. 5, Monoclonal antibodies In Human Engineered, Encyclopedia of Industrial Biotechnology: Bioprocess, Bioseparation, and Cell Technology,","DOI":"10.1002\/9780470054581.eib446"},{"key":"3857_CR18","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-1-60761-451-7_7","volume-title":"Cancer and IgE: Introducing the Concept of AllergoOncology","author":"TR Daniels","year":"2010","unstructured":"Daniels TR, Rodriguez JA, Ortiz-Sanchez O, Helguera G, Penichet ML: The IgE Antibody and Its Use in Cancer Immunotherapy. Cancer and IgE: Introducing the Concept of AllergoOncology. Edited by: Penichet ML, Jensen-Jarolim E. 2010, New York: Springer, 159-184."},{"issue":"10","key":"3857_CR19","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1111\/j.1398-9995.2008.01768.x","volume":"63","author":"E Jensen-Jarolim","year":"2008","unstructured":"Jensen-Jarolim E, Achatz G, Turner MC, Karagiannis S, Legrand F, Capron M, Penichet ML, Rodriguez JA, Siccardi AG, Vangelista L: AllergoOncology: the role of IgE-mediated allergy in cancer. Allergy. 2008, 63 (10): 1255-1266. 10.1111\/j.1398-9995.2008.01768.x.","journal-title":"Allergy"},{"key":"3857_CR20","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1146\/annurev.immunol.17.1.931","volume":"17","author":"JP Kinet","year":"1999","unstructured":"Kinet JP: The high-affinity IgE receptor (Fc epsilon RI): from physiology to pathology. Annu Rev Immunol. 1999, 17: 931-972. 10.1146\/annurev.immunol.17.1.931.","journal-title":"Annu Rev Immunol"},{"key":"3857_CR21","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1146\/annurev.iy.08.040190.003203","volume":"8","author":"DH Conrad","year":"1990","unstructured":"Conrad DH: Fc epsilon RII\/CD23: the low affinity receptor for IgE. Annu Rev Immunol. 1990, 8: 623-645. 10.1146\/annurev.iy.08.040190.003203.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"3857_CR22","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s00262-011-1169-1","volume":"61","author":"TR Daniels","year":"2012","unstructured":"Daniels TR, Martinez-Maza O, Penichet ML: Animal models for IgE-mediated cancer immunotherapy. Cancer Immunol Immunother. 2012, 61 (9): 1535-46. 10.1007\/s00262-011-1169-1.","journal-title":"Cancer Immunol Immunother"},{"key":"3857_CR23","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-60761-451-7","volume-title":"Cancer and IgE: introducing the concept of AllergoOncology","author":"ML Penichet","year":"2010","unstructured":"Penichet ML, Jensen-Jarolim E: Cancer and IgE: introducing the concept of AllergoOncology. 2010, New York: Springer"},{"issue":"7","key":"3857_CR24","doi-asserted-by":"publisher","first-page":"4530","DOI":"10.4049\/jimmunol.0900842","volume":"183","author":"EA Nigro","year":"2009","unstructured":"Nigro EA, Brini AT, Soprana E, Ambrosi A, Dombrowicz D, Siccardi AG, Vangelista L: Antitumor IgE adjuvanticity: key role of Fc epsilon RI. J Immunol. 2009, 183 (7): 4530-4536. 10.4049\/jimmunol.0900842.","journal-title":"J Immunol"},{"issue":"7","key":"3857_CR25","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1007\/s00262-011-1150-z","volume":"61","author":"TR Daniels","year":"2012","unstructured":"Daniels TR, Leuchter RK, Quintero R, Helguera G, Rodr\u00edguez JA, Mart\u00ednez-Maza O, Schultes BC, Nicodemus CF, Penichet ML: Targeting HER2\/neuwith a fully human IgE to harness the allergic reaction against cancer cells. Cancer Immunol Immunother. 2012, 61 (7): 991-1003. 10.1007\/s00262-011-1150-z.","journal-title":"Cancer Immunol Immunother"},{"issue":"36","key":"3857_CR26","doi-asserted-by":"crossref","first-page":"22079","DOI":"10.1016\/S0021-9258(18)45670-0","volume":"265","author":"J Hakimi","year":"1990","unstructured":"Hakimi J, Seals C, Kondas JA, Pettine L, Danho W, Kochan J: The alpha subunit of the human IgE receptor (FceRI) is sufficient for high affinity IgE binding. J Biol Chem. 1990, 265 (36): 22079-22081.","journal-title":"J Biol Chem"},{"issue":"1","key":"3857_CR27","doi-asserted-by":"crossref","first-page":"221","DOI":"10.4049\/jimmunol.157.1.221","volume":"157","author":"TW Wiegand","year":"1996","unstructured":"Wiegand TW, Williams PB, Dreskin SC, Jouvin MH, Kinet JP, Tasset D: High-affinity oligonucleotide ligands to human IgE inhibit binding to Fc epsilon receptor I. J Immunol. 1996, 157 (1): 221-230.","journal-title":"J Immunol"},{"issue":"15","key":"3857_CR28","doi-asserted-by":"publisher","first-page":"1867","DOI":"10.1089\/104303401753153929","volume":"12","author":"RA Willis","year":"2001","unstructured":"Willis RA, Bowers WJ, Turner MJ, Fisher TL, Abdul-Alim CS, Howard DF, Federoff HJ, Lord EM, Frelinger JG: Dendritic cells transduced with HSV-1 amplicons expressing prostate-specific antigen generate antitumor immunity in mice. Hum Gene Ther. 2001, 12 (15): 1867-1879. 10.1089\/104303401753153929.","journal-title":"Hum Gene Ther"},{"issue":"7","key":"3857_CR29","doi-asserted-by":"publisher","first-page":"3428","DOI":"10.1074\/jbc.271.7.3428","volume":"271","author":"JB Lyczak","year":"1996","unstructured":"Lyczak JB, Zhang K, Saxon A, Morrison SL: Expression of novel secreted isoforms of human immunoglobulin E proteins. J Biol Chem. 1996, 271 (7): 3428-3436. 10.1074\/jbc.271.7.3428.","journal-title":"J Biol Chem"},{"issue":"14","key":"3857_CR30","doi-asserted-by":"publisher","first-page":"2864","DOI":"10.1182\/blood-2009-10-250555","volume":"115","author":"C Xuan","year":"2010","unstructured":"Xuan C, Steward KK, Timmerman JM, Morrison SL: Targeted delivery of interferon-alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood. 2010, 115 (14): 2864-2871. 10.1182\/blood-2009-10-250555.","journal-title":"Blood"},{"issue":"4","key":"3857_CR31","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.4049\/jimmunol.157.4.1645","volume":"157","author":"D Dombrowicz","year":"1996","unstructured":"Dombrowicz D, Brini AT, Flamand V, Hicks E, Snouwaert JN, Kinet JP, Koller BH: Anaphylaxis mediated through a humanized high affinity IgE receptor. J Immunol. 1996, 157 (4): 1645-1651.","journal-title":"J Immunol"},{"issue":"4","key":"3857_CR32","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/S1074-7613(00)80556-7","volume":"8","author":"D Dombrowicz","year":"1998","unstructured":"Dombrowicz D, Lin S, Flamand V, Brini AT, Koller BH, Kinet JP: Allergy-associated FcRbeta is a molecular amplifier of IgE- and IgG-mediated in vivo responses. Immunity. 1998, 8 (4): 517-529. 10.1016\/S1074-7613(00)80556-7.","journal-title":"Immunity"},{"issue":"1","key":"3857_CR33","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1084\/jem.183.1.49","volume":"183","author":"WP Fung-Leung","year":"1996","unstructured":"Fung-Leung WP, De Sousa-Hitzler J, Ishaque A, Zhou L, Pang J, Ngo K, Panakos JA, Chourmouzis E, Liu FT, Lau CY: Transgenic mice expressing the human high-affinity immunoglobulin (Ig) E receptor alpha chain respond to human IgE in mast cell degranulation and in allergic reactions. J Exp Med. 1996, 183 (1): 49-56. 10.1084\/jem.183.1.49.","journal-title":"J Exp Med"},{"issue":"19","key":"3857_CR34","doi-asserted-by":"publisher","first-page":"7566","DOI":"10.1073\/pnas.86.19.7566","volume":"86","author":"B Bettler","year":"1989","unstructured":"Bettler B, Hofstetter H, Rao M, Yokoyama WM, Kilchherr F, Conrad DH: Molecular structure and expression of the murine lymphocyte low-affinity receptor for IgE (Fc epsilon RII). Proc Natl Acad Sci USA. 1989, 86 (19): 7566-7570. 10.1073\/pnas.86.19.7566.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"3857_CR35","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nri2273","volume":"8","author":"HJ Gould","year":"2008","unstructured":"Gould HJ, Sutton BJ: IgE in allergy and asthma today. Nat Rev Immunol. 2008, 8 (3): 205-217. 10.1038\/nri2273.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"3857_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1172\/JCI0215640","volume":"110","author":"K Rafiq","year":"2002","unstructured":"Rafiq K, Bergtold A, Clynes R: Immune complex-mediated antigen presentation induces tumor immunity. J Clin Invest. 2002, 110 (1): 71-79. 10.1172\/JCI0215640.","journal-title":"J Clin Invest"},{"issue":"6","key":"3857_CR37","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/14058","volume":"1","author":"A Rodriguez","year":"1999","unstructured":"Rodriguez A, Regnault A, Kleijmeer M, Ricciardi-Castagnoli P, Amigorena S: Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat Cell Biol. 1999, 1 (6): 362-368. 10.1038\/14058.","journal-title":"Nat Cell Biol"},{"issue":"12","key":"3857_CR38","doi-asserted-by":"crossref","first-page":"6285","DOI":"10.4049\/jimmunol.154.12.6285","volume":"154","author":"D Maurer","year":"1995","unstructured":"Maurer D, Ebner C, Reininger B, Fiebiger E, Kraft D, Kinet JP, Stingl G: The high affinity IgE receptor (Fc epsilon RI) mediates IgE-dependent allergen presentation. J Immunol. 1995, 154 (12): 6285-6290.","journal-title":"J Immunol"},{"key":"3857_CR39","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/978-1-4757-9966-8_29","volume":"417","author":"D Maurer","year":"1997","unstructured":"Maurer D, Ebner C, Reininger B, Petzelbauer P, Fiebiger E, Stingl G: Mechanisms of Fc epsilon RI-IgE-facilitated allergen presentation by dendritic cells. Adv Exp Med Biol. 1997, 417: 175-178. 10.1007\/978-1-4757-9966-8_29.","journal-title":"Adv Exp Med Biol"},{"issue":"2","key":"3857_CR40","doi-asserted-by":"crossref","first-page":"607","DOI":"10.4049\/jimmunol.157.2.607","volume":"157","author":"D Maurer","year":"1996","unstructured":"Maurer D, Fiebiger S, Ebner C, Reininger B, Fischer GF, Wichlas S, Jouvin MH, Schmitt-Egenolf M, Kraft D, Kinet JP: Peripheral blood dendritic cells express Fc epsilon RI as a complex composed of Fc epsilon RI alpha- and Fc epsilon RI gamma-chains and can use this receptor for IgE-mediated allergen presentation. J Immunol. 1996, 157 (2): 607-616.","journal-title":"J Immunol"},{"issue":"1\u20133","key":"3857_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1159\/000237500","volume":"113","author":"T Bieber","year":"1997","unstructured":"Bieber T: Fc epsilon RI on human epidermal Langerhans cells: an old receptor with new structure and functions. Int Arch Allergy Immunol. 1997, 113 (1\u20133): 30-34.","journal-title":"Int Arch Allergy Immunol"},{"issue":"8 Pt 1","key":"3857_CR42","doi-asserted-by":"crossref","first-page":"3643","DOI":"10.4049\/jimmunol.150.8.3643","volume":"150","author":"FL Van der Heijden","year":"1993","unstructured":"Van der Heijden FL, Joost Van Neerven RJ, Van Katwijk M, Bos JD, Kapsenberg ML: Serum-IgE-facilitated allergen presentation in atopic disease. J Immunol. 1993, 150 (8 Pt 1): 3643-3650.","journal-title":"J Immunol"},{"issue":"6179","key":"3857_CR43","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/334255a0","volume":"334","author":"TL Stevens","year":"1988","unstructured":"Stevens TL, Bossie A, Sanders VM, Fernandez-Botran R, Coffman RL, Mosmann TR, Vitetta ES: Regulation of antibody isotype secretion by subsets of antigen-specific helper T cells. Nature. 1988, 334 (6179): 255-258. 10.1038\/334255a0.","journal-title":"Nature"},{"issue":"3","key":"3857_CR44","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.vaccine.2005.07.073","volume":"24","author":"G Helguera","year":"2006","unstructured":"Helguera G, Dela Cruz JS, Lowe C, Ng PP, Trinh R, Morrison SL, Penichet ML: Vaccination with novel combinations of anti-HER2\/neu cytokines fusion proteins and soluble protein antigen elicits a protective immune response against HER2\/neu expressing tumors. Vaccine. 2006, 24 (3): 304-316. 10.1016\/j.vaccine.2005.07.073.","journal-title":"Vaccine"},{"issue":"1","key":"3857_CR45","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/BF01741326","volume":"34","author":"E Nagy","year":"1991","unstructured":"Nagy E, Berczi I, Sehon AH: Growth inhibition of murine mammary carcinoma by monoclonal IgE antibodies specific for the mammary tumor virus. Cancer Immunol Immunother. 1991, 34 (1): 63-69. 10.1007\/BF01741326.","journal-title":"Cancer Immunol Immunother"},{"issue":"3","key":"3857_CR46","first-page":"133","volume":"10","author":"MH Kershaw","year":"1998","unstructured":"Kershaw MH, Darcy PK, Trapani JA, MacGregor D, Smyth MJ: Tumor-specific IgE-mediated inhibition of human colorectal carcinoma xenograft growth. Oncol Res. 1998, 10 (3): 133-142.","journal-title":"Oncol Res"},{"issue":"11","key":"3857_CR47","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1002\/(SICI)1521-4141(199911)29:11<3527::AID-IMMU3527>3.0.CO;2-5","volume":"29","author":"HJ Gould","year":"1999","unstructured":"Gould HJ, Mackay GA, Karagiannis SN, O\u2019Toole CM, Marsh PJ, Daniel BE, Coney LR, Zurawski VR, Joseph M, Capron M: Comparison of IgE and IgG antibody-dependent cytotoxicity in vitro and in a SCID mouse xenograft model of ovarian carcinoma. Eur J Immunol. 1999, 29 (11): 3527-3537. 10.1002\/(SICI)1521-4141(199911)29:11<3527::AID-IMMU3527>3.0.CO;2-5.","journal-title":"Eur J Immunol"},{"issue":"4","key":"3857_CR48","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1002\/eji.200323185","volume":"33","author":"SN Karagiannis","year":"2003","unstructured":"Karagiannis SN, Wang Q, East N, Burke F, Riffard S, Bracher MG, Thompson RG, Durham SR, Schwartz LB, Balkwill FR: Activity of human monocytes in IgE antibody-dependent surveillance and killing of ovarian tumor cells. Eur J Immunol. 2003, 33 (4): 1030-1040. 10.1002\/eji.200323185.","journal-title":"Eur J Immunol"},{"issue":"5","key":"3857_CR49","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.4049\/jimmunol.179.5.2832","volume":"179","author":"SN Karagiannis","year":"2007","unstructured":"Karagiannis SN, Bracher MG, Hunt J, McCloskey N, Beavil RL, Beavil AJ, Fear DJ, Thompson RG, East N, Burke F: IgE-antibody-dependent immunotherapy of solid tumors: cytotoxic and phagocytic mechanisms of eradication of ovarian cancer cells. J Immunol. 2007, 179 (5): 2832-2843.","journal-title":"J Immunol"},{"issue":"2","key":"3857_CR50","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1007\/s00262-007-0371-7","volume":"57","author":"SN Karagiannis","year":"2008","unstructured":"Karagiannis SN, Bracher MG, Beavil RL, Beavil AJ, Hunt J, McCloskey N, Thompson RG, East N, Burke F, Sutton BJ: Role of IgE receptors in IgE antibody-dependent cytotoxicity and phagocytosis of ovarian tumor cells by human monocytic cells. Cancer Immunol Immunother. 2008, 57 (2): 247-263.","journal-title":"Cancer Immunol Immunother"},{"issue":"6","key":"3857_CR51","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00262-008-0607-1","volume":"58","author":"P Karagiannis","year":"2009","unstructured":"Karagiannis P, Singer J, Hunt J, Gan SK, Rudman SM, Mechtcheriakova D, Knittelfelder R, Daniels TR, Hobson PS, Beavil AJ: Characterisation of an engineered trastuzumab IgE antibody and effector cell mechanisms targeting HER2\/neu-positive tumour cells. Cancer Immunol Immunother. 2009, 58 (6): 915-930. 10.1007\/s00262-008-0607-1.","journal-title":"Cancer Immunol Immunother"},{"issue":"10","key":"3857_CR52","first-page":"47","volume":"29","author":"J Hoff","year":"2000","unstructured":"Hoff J: Methods of blood collection in the mouse. Lab Anim. 2000, 29 (10): 47-53.","journal-title":"Lab Anim"},{"issue":"1","key":"3857_CR53","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.mcna.2010.08.024","volume":"95","author":"CK Gjertson","year":"2011","unstructured":"Gjertson CK, Albertsen PC: Use and assessment of PSA in prostate cancer. Med Clin North Am. 2011, 95 (1): 191-200. 10.1016\/j.mcna.2010.08.024.","journal-title":"Med Clin North Am"},{"key":"3857_CR54","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1080\/713783586","volume":"233","author":"WM Zhang","year":"2000","unstructured":"Zhang WM, Finne P, Leinonen J, Stenman UH: Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases. Scand J Clin Lab Invest. 2000, 233: 51-58.","journal-title":"Scand J Clin Lab Invest"},{"issue":"1","key":"3857_CR55","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/0014-5793(81)81097-6","volume":"128","author":"L Sottrup-Jensen","year":"1981","unstructured":"Sottrup-Jensen L, Petersen TE, Magnusson S: Mechanism of proteinase complex formation with alpha 2-macroglobulin. Three modes of trypsin binding. FEBS Lett. 1981, 128 (1): 127-132. 10.1016\/0014-5793(81)81097-6.","journal-title":"FEBS Lett"},{"issue":"12","key":"3857_CR56","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1093\/clinchem\/44.12.2471","volume":"44","author":"WM Zhang","year":"1998","unstructured":"Zhang WM, Finne P, Leinonen J, Vesalainen S, Nordling S, Rannikko S, Stenman UH: Characterization and immunological determination of the complex between prostate-specific antigen and alpha2-macroglobulin. Clin Chem. 1998, 44 (12): 2471-2479.","journal-title":"Clin Chem"},{"issue":"3","key":"3857_CR57","first-page":"343","volume":"86","author":"R Bheekha Escura","year":"1995","unstructured":"Bheekha Escura R, Wasserbauer E, Hammerschmid F, Pearce A, Kidd P, Mudde GC: Regulation and targeting of T-cell immune responses by IgE and IgG antibodies. Immunology. 1995, 86 (3): 343-350.","journal-title":"Immunology"},{"issue":"8","key":"3857_CR58","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1007\/s00262-003-0377-8","volume":"52","author":"NG Chakraborty","year":"2003","unstructured":"Chakraborty NG, Stevens RL, Mehrotra S, Laska E, Taxel P, Sporn JR, Schauer P, Albertsen PC: Recognition of PSA-derived peptide antigens by T cells from prostate cancer patients without any prior stimulation. Cancer Immunol Immunother. 2003, 52 (8): 497-505. 10.1007\/s00262-003-0377-8.","journal-title":"Cancer Immunol Immunother"},{"issue":"4","key":"3857_CR59","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1097\/01.cji.0000165353.19171.41","volume":"28","author":"AM Miller","year":"2005","unstructured":"Miller AM, Ozenci V, Kiessling R, Pisa P: Immune monitoring in a phase 1 trial of a PSA DNA vaccine in patients with hormone-refractory prostate cancer. J Immunother. 2005, 28 (4): 389-395. 10.1097\/01.cji.0000165353.19171.41.","journal-title":"J Immunother"},{"issue":"2","key":"3857_CR60","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1046\/j.1365-2249.1998.00678.x","volume":"114","author":"JM Corman","year":"1998","unstructured":"Corman JM, Sercarz EE, Nanda NK: Recognition of prostate-specific antigenic peptide determinants by human CD4 and CD8 T cells. Clin Exp Immunol. 1998, 114 (2): 166-172. 10.1046\/j.1365-2249.1998.00678.x.","journal-title":"Clin Exp Immunol"},{"issue":"2","key":"3857_CR61","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1084\/jem.181.2.713","volume":"181","author":"CS Hsieh","year":"1995","unstructured":"Hsieh CS, Macatonia SE, O\u2019Garra A, Murphy KM: T cell genetic background determines default T helper phenotype development in vitro. J Exp Med. 1995, 181 (2): 713-721. 10.1084\/jem.181.2.713.","journal-title":"J Exp Med"},{"issue":"10","key":"3857_CR62","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.1084\/jem.186.10.1623","volume":"186","author":"RS Chu","year":"1997","unstructured":"Chu RS, Targoni OS, Krieg AM, Lehmann PV, Harding CV: CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity. J Exp Med. 1997, 186 (10): 1623-1631. 10.1084\/jem.186.10.1623.","journal-title":"J Exp Med"},{"issue":"6","key":"3857_CR63","doi-asserted-by":"publisher","first-page":"608","DOI":"10.1016\/j.ajog.2009.12.001","volume":"202","author":"CF Nicodemus","year":"2010","unstructured":"Nicodemus CF, Wang L, Lucas J, Varghese B, Berek JS: Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol. 2010, 202 (6): 608-e601-608","journal-title":"Am J Obstet Gynecol"},{"issue":"5","key":"3857_CR64","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/pro.5560050505","volume":"5","author":"BO Villoutreix","year":"1996","unstructured":"Villoutreix BO, Lilja H, Pettersson K, Lovgren T, Teleman O: Structural investigation of the alpha-1-antichymotrypsin: prostate-specific antigen complex by comparative model building. Protein Sci. 1996, 5 (5): 836-851.","journal-title":"Protein Sci"},{"issue":"12","key":"3857_CR65","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1002\/mrd.20910","volume":"75","author":"V Kumar","year":"2008","unstructured":"Kumar V, Hassan MI, Kashav T, Singh TP, Yadav S: Heparin-binding proteins of human seminal plasma: purification and characterization. Mol Reprod Dev. 2008, 75 (12): 1767-1774. 10.1002\/mrd.20910.","journal-title":"Mol Reprod Dev"},{"issue":"6","key":"3857_CR66","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1007\/s12038-009-0104-5","volume":"34","author":"V Kumar","year":"2009","unstructured":"Kumar V, Hassan MI, Tomar AK, Kashav T, Nautiyal J, Singh S, Singh TP, Yadav S: Proteomic analysis of heparin-binding proteins from human seminal plasma: a step towards identification of molecular markers of male fertility. J Biosci. 2009, 34 (6): 899-908. 10.1007\/s12038-009-0104-5.","journal-title":"J Biosci"},{"issue":"3","key":"3857_CR67","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/pros.2990140303","volume":"14","author":"FJ Meyers","year":"1989","unstructured":"Meyers FJ, Denardo SJ, Macey D, White RD, Unger M: Development of monoclonal antibody imaging of metastatic prostatic carcinoma. Prostate. 1989, 14 (3): 209-220. 10.1002\/pros.2990140303.","journal-title":"Prostate"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-13-195\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-13-195","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T03:58:56Z","timestamp":1688183936000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-13-195"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4,17]]},"references-count":67,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,12]]}},"alternative-id":["3857"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-13-195","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4,17]]},"article-number":"195"}}